BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer

Figure 1 Construction of trastuzul tumor resistance model. A: The morphology of the resistant strain NCI-N87R is similar to that of the parent cell line NCI-N87; B: Cells were treated with 1000 μg/mL trastuzumab for 4 days, and cell viabilities were detected by cell counting kit-8 assay. ^bP < 0.0001. CCK8: Cell counting kit-8; Tra: Trastuzumab.